A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma

Inclusion Criteria:

• Have a diagnosis of multiple myeloma according to the International Myeloma WorkingGroup (IMWG) diagnostic criteria

• Be newly diagnosed and not considered a candidate for high-dose chemotherapy withautologous stem cell transplant (ASCT) due to: ineligible due to advanced age OR;ineligible due to the presence of comorbid condition(s) likely to have a negativeimpact on tolerability of high-dose chemotherapy with ASCT OR; deferral of high-dosechemotherapy with ASCT as initial treatment

• Have an Eastern Cooperative Oncology Group (ECOG) performance status score of 0 to 2

• A participant must agree not to be pregnant, breastfeeding, or planning to becomepregnant while enrolled in this study or within 6 months after the last dose ofstudy treatment

• A participant must agree not to plan to father a child while enrolled in this studyor within 100 days after the last dose of study treatment

Exclusion Criteria:

• Received any prior therapy for multiple myeloma or smoldering myeloma other than ashort course of corticosteroids (not to exceed total of 160 milligrams [mg]dexamethasone or equivalent). In addition, received a cumulative dose of systemiccorticosteroids equivalent to greater than or equals to (>=) 20 mg of dexamethasonewithin 14 days before randomization

• Had plasmapheresis within 28 days of randomization

• Had a stroke, transient ischemic attack, or seizure within 6 months prior torandomization

• Known allergies, hypersensitivity, or intolerance to teclistamab or talquetamabexcipients

• Known contraindications to the use of daratumumab or lenalidomide per localprescribing information

• Myeloma Frailty Index of >=2 with the exception of participants who have a score of 2 based on age alone